Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Investing.com - RBC Capital has lowered its price target on Regenxbio Inc . (NASDAQ:RGNX) to $17.00 from $21.00 while maintaining an Outperform rating following the company’s second-quarter report. According to InvestingPro data, the stock currently trades at $7.79, significantly below analyst targets ranging from $13 to $52, suggesting potential upside. The company’s financial health score is rated as "Fair" by InvestingPro analysts.
The firm noted that Regenxbio’s Duchenne muscular dystrophy (DMD) pivotal trial is ongoing with a Biologics License Application filing expected in mid-2026. Regenxbio has reiterated confidence in its ability to avoid liver toxicity issues that affected Sarepta Therapeutics (NASDAQ:SRPT), citing its differentiated prophylactic approach using sirolimus and eculizumab in addition to steroids, along with a higher empty-to-full capsid ratio. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 2.93x, providing runway for its clinical programs.
On its diabetic retinopathy program, Regenxbio and partner AbbVie (NYSE:ABBV) shared encouraging two-year durability data showing 50% of patients responded to therapy versus 21% at one year. The companies have amended their agreement to split a $200 million milestone into two $100 million tranches, contingent on AbbVie initiating a second Phase III trial.
Regenxbio also confirmed its MPSII therapy has a PDUFA date of November 9, 2025, which may result in a Priority Review Voucher if approved. The company noted that despite recent leadership changes at the FDA’s Center for Biologics Evaluation and Research, its review team has not materially changed and remains fully engaged.
RBC Capital cited Regenxbio’s undemanding valuation, potential benefit from Sarepta’s recent setback, and promising data across multiple programs as reasons for maintaining its Outperform rating despite the lower price target. InvestingPro analysis indicates the stock is currently undervalued, with impressive revenue growth of 80.7% over the last twelve months. For deeper insights into RGNX’s valuation and growth prospects, including 8 additional ProTips and comprehensive financial analysis, check out the full Pro Research Report available on InvestingPro.
In other recent news, Regenxbio Inc. reported its second-quarter 2025 earnings, which did not meet analyst expectations. The company announced an earnings per share (EPS) of -$1.38, falling short of the forecasted -$0.94. Additionally, Regenxbio’s revenue was reported at $21.36 million, significantly below the projected $38.7 million. These results highlight a notable shortfall in both earnings and revenue for the quarter. The earnings miss and revenue shortfall have drawn attention from investors and analysts alike. This development is part of a series of recent updates concerning the company. Analysts continue to monitor the company’s financial performance closely. Such financial results are crucial for stakeholders assessing the company’s current position and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.